| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 84556 |
cas:2353409-54-6 ， Mal-amido-PEG8-Val-Gly，ADC定制 |
186 |
wyh |
2024-12-19 |
| 84557 |
Azido-PEG4-Val-Ala-PAB-PNP |
187 |
zyl |
2024-12-19 |
| 84558 |
NOTA-(NGR)2 NOTA偶联NGR二聚体 |
145 |
h |
2024-12-19 |
| 84559 |
1-(2,5-dioxopyrrolidin-1-yloxy)-4-((5-nitropyridin-2-yl)disulfanyl)-1-oxobutane-2-sulfonic acid，ADC定制 |
133 |
wyh |
2024-12-19 |
| 84560 |
CAS: 1343476-44-7，Val-Ala-PAB-OH |
138 |
WYQ |
2024-12-19 |
| 84561 |
MC-PBD， ADC试剂 |
169 |
kx |
2024-12-19 |
| 84562 |
Mal-Val-Ala-PAB的介绍 |
173 |
zyl |
2024-12-19 |
| 84563 |
DOTA-K-A9 1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸(DOTA)结合肽A9 |
156 |
h |
2024-12-19 |
| 84564 |
Azide-PEG3-Val-Cit-PAB-MMAF，叠氮-三聚乙二醇-Val-Cit-PAB-MMAF |
149 |
WYQ |
2024-12-19 |
| 84565 |
Arm-DOTA-B72.3 |
158 |
h |
2024-12-19 |
| 84566 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
166 |
zyl |
2024-12-19 |
| 84567 |
(Lys(DOTA)4)BVD15 DOTA偶联神经肽Y(NPY)类似物 |
242 |
h |
2024-12-19 |
| 84568 |
1801838-28-7，Mc-vc-PAB-SN38，化合物MC-VC-PAB-SN38 |
160 |
kx |
2024-12-19 |
| 84569 |
DOTA-PPI 1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸(DOTA)-官能化的聚(丙烯亚胺)(PPI)糖树枝状分子 |
161 |
h |
2024-12-19 |
| 84570 |
CAS: 863971-17-9，MC-Val-Cit-PAB-MMAF |
172 |
WYQ |
2024-12-19 |
| 84571 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
203 |
zyl |
2024-12-19 |
| 84572 |
DBCO-PEG4-vc-PAB-MMAE， ADC试剂 |
200 |
kx |
2024-12-19 |
| 84573 |
1884578-00-0，Boc-PEG4-Val-Ala-PAB-PNP，ADC定制 |
184 |
wyh |
2024-12-19 |
| 84574 |
DOTA-Peg-Cpa-c[DCys-Aph(Cbm)-DTrp-Lys-Thr-Cys]-2Nal-NH2 |
152 |
h |
2024-12-19 |
| 84575 |
DOTA-2.5D DOTA-胱氨酸结肽(knottins)2.5D和2.5F |
196 |
h |
2024-12-19 |
| 84576 |
二苯并环辛炔-四聚乙二醇-VAL-ALA-PAB，ADC定制 |
174 |
wyh |
2024-12-19 |
| 84577 |
Hz220(DOTA-Lys(IR dye 650)-PEa(4)-[D-Phe(6)DOTA偶联的GRPr拮抗剂 |
173 |
h |
2024-12-19 |
| 84578 |
Azido-PEG4-MMAE，抗体药物偶联物（ADCs） |
190 |
WYQ |
2024-12-19 |
| 84579 |
1626359-62-3，SPDB-DM4， ADC试剂 |
142 |
kx |
2024-12-19 |
| 84580 |
Acid-PEG4-Val-Cit-PAB-MMAE，包含PEG链和MMAE等部分 |
174 |
WYQ |
2024-12-19 |
| 84581 |
cas:159857-70-2，MC-Val-Cit-Doxorubicin，ADC定制 |
166 |
wyh |
2024-12-19 |
| 84582 |
DOTA-(D)Phe(1)-Tyr(3) |
159 |
h |
2024-12-19 |
| 84583 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
190 |
zyl |
2024-12-19 |
| 84584 |
FAM-amido hexamethylene carbamate-PAB-Cit-Val-Alkyne |
204 |
WYQ |
2024-12-19 |
| 84585 |
DOTA-l-Nal3-octreotide DOTA-l-nal3-奥曲肽 |
160 |
h |
2024-12-19 |
| 84586 |
CAS: 2762518-86-3 ，NHS ester-PEG4-Val-Cit-PAB-MMAE |
170 |
WYQ |
2024-12-19 |
| 84587 |
cas:2873452-49-2 ； MC-EVCit-PAB-MMAE，ADC定制 |
185 |
wyh |
2024-12-19 |
| 84588 |
CAS: 2762519-08-2 endo-BCN-PEG4-Val-Cit-PAB-MMAE，内末端二苯卡宾吡啶甲酸乙酯聚乙二醇4个单元赖氨酸缬氨酸丙氨酸天冬氨酸 |
193 |
WYQ |
2024-12-19 |
| 84589 |
cas:863971-24-8，Mc-MMAE ，马来酰亚胺基己酰-单甲基澳瑞他汀 E |
227 |
kx |
2024-12-19 |
| 84590 |
DOTA-(AEEA)2-BN DOTA-(AEEA)2-铃蟾肽 |
179 |
h |
2024-12-19 |
| 84591 |
cas:2259318-55-1 ， DBCO-(PEG2-VC-PAB-MMAE)2，ADC定制 |
175 |
wyh |
2024-12-19 |
| 84592 |
cas:1394238-91-5 Fmoc-Val-Ala-PAB |
193 |
zyl |
2024-12-19 |
| 84593 |
CAS: 2285373-84-2 Ethyl (S)-1-((1-((4-((((4-nitrophenoxy)carbonyl) oxy)methyl)phenyl)amino)-1-oxo-5-ureidopenta n-2-yl)carbamoyl)cyclobutane-1-carboxylate |
216 |
WYQ |
2024-12-19 |
| 84594 |
Azido-Phenyl-Amido-SS-Sulfo-NHS Ester， ADC试剂 |
200 |
kx |
2024-12-19 |
| 84595 |
DOTA-βala-K-NOTA-BBN(7-14)NH2 |
179 |
h |
2024-12-19 |
| 84596 |
DBCO-PEG3-acetic-Val-Cit-PAB，主要用于合成抗体偶联药物（ADC） |
176 |
WYQ |
2024-12-19 |
| 84597 |
Mal-PEG4-Val-Ala-PAB-PNP，ADC定制 |
151 |
wyh |
2024-12-19 |
| 84598 |
cas:330970-70-2 Alloc-Val-Ala-OH |
195 |
zyl |
2024-12-19 |
| 84599 |
DOTA-somatostatin receptor analogs DOTA生长抑素受体类似物 |
183 |
h |
2024-12-19 |
| 84600 |
CAS: 2754384-60-4，DBCO-(PEG)3-VC-PAB-MMAE |
168 |
WYQ |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询